The OS at 5 years was 70, 59 and 41% for patients with Lille score 0, 1 and 2, respectively (P=0.038, when age adjustment was made). Patients treated with RIC experienced significantly less aGVHD compared with patients treated with MAC (P<0.001). The probability of survival at 5 years was 49% for the MAC-treated patients and 59% in the RIC group (P=0.125). No significant difference was found in TRM at 100 days between the MAC- and the RIC-treated patients. The type of stem cell donor did not significantly affect the survival. Among the RIC patients, the survival was significantly (P=0.003) better for the patients with age <60 years (a 10-year survival close to 80%) than for the older patients. When adjustment for age differences was made, the survival of the patients treated with RIC was significantly better (P=0.003). The mean age in the two groups at transplantation was 46☑2 and 55☘ years, respectively (P<0.001). Myeloablative conditioning (MAC) was given to 40 patients, and reduced intensity conditioning (RIC) was used in 52 patients. Between 19 a total of 92 patients with myelofibrosis (MF) in chronic phase underwent allo-SCT in nine Nordic transplant centers.
